Adaptive Biotechnologies Corporation (ADPT) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ADPT Insider Trading Activity
ADPT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $11,297,479 | 21 | 100 |
Related Transactions
| NEUPERT PETER M | director | 0 | $0 | 1 | $70,500 | $-70,500 |
| PISKEL KYLE | Chief Financial Officer | 0 | $0 | 2 | $73,307 | $-73,307 |
| Taylor Stacy L | SVP and General Counsel | 0 | $0 | 1 | $121,079 | $-121,079 |
| LO FRANCIS | Chief People Officer | 0 | $0 | 1 | $145,845 | $-145,845 |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | 0 | $0 | 1 | $181,641 | $-181,641 |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | 0 | $0 | 1 | $311,792 | $-311,792 |
| GRIFFIN MICHELLE RENEE | director | 0 | $0 | 2 | $385,304 | $-385,304 |
| HERSHBERG ROBERT | director | 0 | $0 | 1 | $402,270 | $-402,270 |
| RUBINSTEIN JULIE | President and COO | 0 | $0 | 1 | $415,540 | $-415,540 |
| ROBINS HARLAN S | Chief Scientific Officer | 0 | $0 | 3 | $1.19M | $-1.19M |
| ROBINS CHAD M | CEO and Chairman | 0 | $0 | 7 | $8M | $-8M |
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Insider Activity of Adaptive Biotechnologies Corporation
Over the last 12 months, insiders at Adaptive Biotechnologies Corporation have bought $0 and sold $11.3M worth of Adaptive Biotechnologies Corporation stock.
On average, over the past 5 years, insiders at Adaptive Biotechnologies Corporation have bought $0 and sold $82.56M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 250,000 shares for transaction amount of $5M was made by VIKING GLOBAL PERFORMANCE LLC (10 percent owner) on 2019‑07‑01.
List of Insider Buy and Sell Transactions, Adaptive Biotechnologies Corporation
| 2025-05-01 | Sale | ROBINS HARLAN S | Chief Scientific Officer | 68,412 0.046% | $7.35 | $502,828 | +27.16% | |
| 2025-03-24 | Sale | ROBINS HARLAN S | Chief Scientific Officer | 1,698 0.0012% | $9.00 | $15,282 | -10.62% | |
| 2025-03-13 | Sale | GRIFFIN MICHELLE RENEE | director | 36,291 0.0245% | $7.19 | $260,932 | +7.88% | |
| 2025-03-12 | Sale | HERSHBERG ROBERT | director | 53,000 0.0355% | $7.59 | $402,270 | +1.44% | |
| 2025-03-10 | Sale | NEUPERT PETER M | director | 10,000 0.0071% | $7.05 | $70,500 | +15.59% | |
| 2025-03-06 | Sale | ROBINS CHAD M | CEO and Chairman | 102,218 0.068% | $7.64 | $780,946 | -0.90% | |
| 2025-03-06 | Sale | GRIFFIN MICHELLE RENEE | director | 15,664 0.0108% | $7.94 | $124,372 | -0.90% | |
| 2025-03-05 | Sale | ROBINS CHAD M | CEO and Chairman | 117,351 0.0698% | $6.98 | $819,471 | -4.05% | |
| 2025-03-05 | Sale | ROBINS HARLAN S | Chief Scientific Officer | 96,656 0.0575% | $6.99 | $675,219 | -4.05% | |
| 2025-03-05 | Sale | RUBINSTEIN JULIE | President and COO | 59,505 0.0354% | $6.98 | $415,540 | -4.05% | |
| 2025-03-05 | Sale | BENZENO SHARON | Chief Commercial Ofc Imm Med | 44,665 0.0266% | $6.98 | $311,792 | -4.05% | |
| 2025-03-05 | Sale | BOBULSKY SUSAN | Chief Commercial Officer, MRD | 26,023 0.0155% | $6.98 | $181,641 | -4.05% | |
| 2025-03-05 | Sale | LO FRANCIS | Chief People Officer | 20,875 0.0124% | $6.99 | $145,845 | -4.05% | |
| 2025-03-05 | Sale | PISKEL KYLE | Chief Financial Officer | 10,320 0.0061% | $6.98 | $72,072 | -4.05% | |
| 2025-02-20 | Sale | ROBINS CHAD M | CEO and Chairman | 99,107 0.0677% | $8.44 | $836,463 | -6.72% | |
| 2025-02-19 | Sale | ROBINS CHAD M | CEO and Chairman | 186,080 0.129% | $8.46 | $1.57M | -6.87% | |
| 2025-02-18 | Sale | ROBINS CHAD M | CEO and Chairman | 211,160 0.146% | $8.50 | $1.79M | -5.44% | |
| 2025-02-14 | Sale | ROBINS CHAD M | CEO and Chairman | 158,921 0.1069% | $8.46 | $1.34M | -6.03% | |
| 2025-02-13 | Sale | ROBINS CHAD M | CEO and Chairman | 100,287 0.076% | $8.44 | $846,422 | -8.04% | |
| 2024-11-18 | Sale | PISKEL KYLE | Chief Financial Officer | 248 0.0001% | $4.98 | $1,235 | +61.11% |
Insider Historical Profitability
| ROBINS CHAD M | CEO and Chairman | 2959249 1.9479% | $27.49M | 0 | 70 | |
| ROBINS HARLAN S | Chief Scientific Officer | 1279524 0.8423% | $11.89M | 0 | 3 | |
| RUBINSTEIN JULIE | President and COO | 588249 0.3872% | $5.46M | 0 | 63 | |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | 392723 0.2585% | $3.65M | 0 | 3 | |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | 347238 0.2286% | $3.23M | 0 | 4 | |
| LO FRANCIS | Chief People Officer | 332846 0.2191% | $3.09M | 0 | 18 | |
| PISKEL KYLE | Chief Financial Officer | 269010 0.1771% | $2.5M | 0 | 6 | |
| NEUPERT PETER M | director | 224690 0.1479% | $2.09M | 0 | 1 | |
| Taylor Stacy L | SVP and General Counsel | 139365 0.0917% | $1.29M | 0 | 25 | |
| HERSHBERG ROBERT | director | 69690 0.0459% | $647,420.10 | 0 | 1 | |
| GRIFFIN MICHELLE RENEE | director | 15394 0.0101% | $143,010.26 | 0 | 16 | |
| SPH Group Holdings LLC | 10 percent owner | 41031674 27.0093% | $381.18M | 25 | 0 | |
| STEEL PARTNERS II LP | 10 percent owner | 37094472 24.4176% | $344.61M | 161 | 0 | |
| VIKING GLOBAL PERFORMANCE LLC | 10 percent owner | 30993708 20.4017% | $287.93M | 1 | 2 | <0.0001% |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 29993708 19.7435% | $278.64M | 0 | 1 | |
| GOEL DAVID E. | See Remarks | 12309090 8.1025% | $114.35M | 0 | 4 | |
| ZOLTNERS ANDRIS A | director | 3621016 2.3835% | $33.64M | 0 | 1 | |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 10 percent owner | 1594352 1.0495% | $14.81M | 0 | 1 | |
| Sterling Capital Partners III, LLC | 1009813 0.6647% | $9.38M | 0 | 4 | ||
| PETERSON TYCHO | Chief Financial Officer | 531553 0.3499% | $4.94M | 0 | 4 | |
| Sundaresh Subramanian | President & CEO | 333518 0.2195% | $3.1M | 1 | 0 | |
| SOOD NITIN | Chief Commercial Officer, MRD | 214808 0.1414% | $2M | 0 | 5 | |
| ADAMS R MARK | Chief Operating Officer | 175361 0.1154% | $1.63M | 0 | 8 | |
| Goyal Manoj | VP, Global Product Development | 109000 0.0717% | $1.01M | 0 | 1 | |
| OMEARA CHRISTOPHER G | VP Corp, Fin/CFO | 100000 0.0658% | $929,000.00 | 0 | 1 | |
| Westfield John M | VP, Corp. Controller | 30721 0.0202% | $285,398.09 | 0 | 4 | |
| Noellert John | VP, World Wide Sales | 16666 0.011% | $154,827.14 | 0 | 2 | |
| Lowe Marcus D | VP, Marketing & Business Dev. | 13333 0.0088% | $123,863.57 | 0 | 4 | |
| Palaniappan Jyoti | SVP, Diagnostics, T-Detect | 9158 0.006% | $85,077.82 | 0 | 6 | |
| Pellini Michael J | director | 1504 0.001% | $13,972.16 | 0 | 3 | |
| DOBMEIER ERIC | director | 0 0% | $0 | 0 | 8 | |
| Dotz Mary | Chief Financial Officer | 0 0% | $0 | 1 | 2 | |
| SANG CHARLES | SVP, External Affairs | 0 0% | $0 | 0 | 4 |
Historical Insider Profitability vs. Competitors
$831,902,292 | 108 | 9.34% | $1.43B | |
$54,590,806 | 65 | 21.84% | $1.12B | |
$100,002,191 | 42 | 21.48% | $1.37B | |
$530,111,731 | 35 | 8.69% | $1.15B | |
$148,770,544 | 34 | 80.63% | $1.38B | |
$309,951,506 | 30 | 32.56% | $1.14B | |
$1,295,059 | 29 | 102.78% | $1.3B | |
$150,253,463 | 26 | -52.83% | $1.65B | |
$1,272,896 | 16 | 24.56% | $1.07B | |
$154,554,190 | 14 | 29.60% | $1.66B | |
$92,580,864 | 14 | -1.28% | $1.57B | |
$137,013,690 | 11 | 26.62% | $1.65B | |
$45,445,266 | 9 | -24.96% | $1.53B | |
$32,575,266 | 8 | 37.03% | $1.74B | |
$107,098,946 | 7 | 1.61% | $1.5B | |
$21,792,890 | 6 | 75.72% | $1.31B | |
$91,325,021 | 6 | 1.83% | $1.38B | |
$10,000,009 | 1 | 100.92% | $1.61B | |
Adaptive Biotechnologies Corporation (ADPT) | $5,000,000 | 1 | -22.84% | $1.41B |
ADPT Institutional Investors: Active Positions
| Increased Positions | 116 | +59.18% | 14M | +9.87% |
| Decreased Positions | 73 | -37.24% | 11M | -7.66% |
| New Positions | 44 | New | 3M | New |
| Sold Out Positions | 24 | Sold Out | 1M | Sold Out |
| Total Postitions | 239 | +21.94% | 142M | +2.21% |
ADPT Ownership Change vs Market
Institutional Investor Ownership
| Viking Global Investors Lp | $295,138.00 | 19.73% | 29.99M | 0 | 0% | 2024-12-31 |
| Rubric Capital Management Lp | $143,664.00 | 9.61% | 14.6M | +200,000 | +1.39% | 2024-12-31 |
| Blackrock, Inc. | $120,341.00 | 8.05% | 12.23M | +108,947 | +0.9% | 2025-03-31 |
| Vanguard Group Inc | $105,434.00 | 7.05% | 10.71M | +75,448 | +0.71% | 2024-12-31 |
| Ark Investment Management Llc | $92,733.00 | 6.2% | 9.42M | -2M | -18.77% | 2024-12-31 |
| Nikko Asset Management Americas, Inc. | $67,238.00 | 4.5% | 6.83M | -900,747 | -11.65% | 2024-12-31 |
| Millennium Management Llc | $61,920.00 | 4.14% | 6.29M | -3M | -33.06% | 2024-12-31 |
| Sumitomo Mitsui Trust Group, Inc. | $59,883.00 | 4% | 6.09M | -747,447 | -10.94% | 2025-03-31 |
| Soleus Capital Management, L.P. | $29,354.00 | 1.96% | 2.98M | +2M | +168.09% | 2024-12-31 |
| Aristotle Atlantic Partners, Llc | $28,405.00 | 1.9% | 2.89M | -114,499 | -3.81% | 2024-12-31 |